Effect of nalorphine and antiparkinsonian drugs on methadone-induced rigidity; relation to homovanillic acid content of nucleus caudatus.
D000547:Amantadine / Q000494:pharmacology*; D000818:Animals; D001285:Atropine / Q000494:pharmacology*; D001831:Body Temperature / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D002421:Caudate Nucleus / Q000378:metabolism*; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008297:Male; D008691:Methadone / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D009127:Muscle Rigidity; D009129:Muscle Tonus / Q000187:drug effects; D009269:Nalorphine / Q000494:pharmacology*; D010276:Parasympatholytics / Q000494:pharmacology; D010648:Phenylacetates / Q000378:metabolism*; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D013050:Spectrometry, Fluorescence; D014282:Trihexyphenidyl / Q000494:pharmacology
D010276:Parasympatholytics; D010648:Phenylacetates; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D014282:Trihexyphenidyl; D001285:Atropine; D000547:Amantadine; D009269:Nalorphine; D008691:Methadone; D006719:Homovanillic Acid